Overview
Sage Therapeutics is a biopharmaceutical company pioneering GABA and NMDA receptor-targeted medicines for brain health disorders, with Zurzuvae (zuranolone) being the first once-daily oral pill FDA-approved for postpartum depression. They continue to advance a pipeline targeting major depressive disorder, epilepsy, and essential tremor.
More in Neuropharmaceuticals
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
💊 Neuropharmaceuticals
Location
Cambridge, MA, USA
Funding
NASDAQ: SAGE
Website
sagerx.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →